Four-year follow-up of a patient with mixed cardiomyopathy and an implanted cardiac contractility modulation device: a case report
T. M. Uskach,
A. A. Safiullina,
Yu. Sh. Sharapova,
V. A. Amanatova,
A. A. Petrukhina,
M. I. Makeev,
S. N. Tereshchenko https://doi.org/10.15829/1728-8800-2021-2811
Abstract
The article presents a case report of a 28-year-old male patient with mixed dilated cardiomyopathy: myocardial noncompaction and chemotherapy-related cardiotoxicity, which led to severe heart failure (HF). With optimal drug therapy, the patient was implanted with a cardiac contractility modulation device in order to improve exercise tolerance, quality of life and relieve HF symptoms. Complex therapy has led to significant clinical and echocardiographic improvement. This case demonstrates a 4-year follow-up of a patient with a reduced left ventricular ejection fraction and an implanted cardiac contractility modulation device, whose condition, after several severe HF decompensations, was stabilized.
About the Authors
T. M. Uskach
National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Moscow.
A. A. Safiullina
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow.
Yu. Sh. Sharapova
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow.
Tel.: +7 (916) 071-00-45
V. A. Amanatova
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow.
A. A. Petrukhina
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow.
M. I. Makeev
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow.
S. N. Tereshchenko
National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Moscow.
References
1. Tereshchenko SN, Zhirov IV. Chronic heart failure: New challenges and new perspectives. Terapevticheskii arkhiv. 2017;89(9):4-9. (In Russ.)
2. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2020;25(11):4083. (In Russ.)
3. Pavlenko EV, Blagova OV, Varionchik NV, et al. Register of adult patients with noncompact left ventricular myocardium: classification of clinical forms and a prospective assessment of progression. Russian Journal of Cardiology. 2019;(2):12-25. (In Russ.)
4. Shemisa K, Li J, Tam M, Barcena J. Left ventricular noncompaction cardiomyopathy. Cardiovasc Diagn Ther. 2013;3(3):170-5. doi:10.3978/j.issn.2223-3652.2013.05.04.
5. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.
6. Giallauria F, Cuomo G, Parlato A, et al. A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life. ESC Heart Fail. 2020;7(5):2922-32. doi:10.1002/ehf2.12902.
7. Kloppe A, Lawo T, Mijic D, et al. Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration. Int J Cardiol. 2016;209:291-5. doi:10.1016/j.ijcard.2016.02.001.
8. Pappone C, Vicedomini G, Salvati A, et al. Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure. Heart Fail Rev. 2001;6(1):55-60. doi:10.1023/a:1009807309006.
9. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol. 2001;33(6):1053-63. doi:10.1006/jmcc.2001.1366.
10. Kuschyk J, Roeger S, Schneider R, et al. Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients. Int J Cardiol. 2015;183:76-81. doi:10.1016/j.ijcard.2014.12.178.
11. Schau T, Seifert M, Meyhofer J, et al. Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace. 2011;13(10):1436-44. doi:10.1093/europace/eur153.
12. Abraham WT, Kuck KH, Goldsmith RL, et al. Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-83. doi:10.1016/j.jchf.2018.04.010.
13. Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Fail. 2019;21(9):1103-13. doi:10.1002/ejhf.1374.
14. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101-5. doi:10.1016/j.jacc.2005.03.045.
15. Grothoff M, Pachowsky M, Hoffmann J, et al. Value of car- 25. diovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol. 2012;22(12):2699-709. doi:10.1007/s00330-012-2554-7.
16. Jacquier A, Thuny F, Jop B, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31(9):1098-104. doi:10.1093/eurheartj/ehp595.
17. van Dalen BM, Caliskan K, Soliman OI, et al. Left ventricular solid body rotation in non-compaction cardiomyopathy: a potential new objective and quantitative functional diagnostic criterion? Eur J Heart Fail. 2008;10(11):1088-93. doi:10.1016/j.ejheart.2008.08.006.
18. Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm. 2006;3(10):1140-7. doi:10.1016/j.hrthm.2006.06.031.
19. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019-28. doi:10.1093/eurheartj/ehn020.
20. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2):329-37.e1-2. doi:10.1016/j.ahj.2010.10.025.
21. Kleemann T. Cardiac contractility modulation. A new form of therapy for patients with heart failure and narrow QRS complex? Herz. 2015;40(7):945-51. doi:10.1007/s00059-015-4362-8.
22. Stix G, Borggrefe M, Wolpert C, et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J. 2004;25(8):650-5. doi:10.1016/j.ehj.2004.02.027.
23. Lyon AR, Samara MA, Feldman DS. Cardiac contractility modulation therapy in advanced systolic heart failure. Nat Rev Cardiol. 2013;10(10):584-98. doi:10.1038/nrcardio.2013.114.
24. Imai M, Rastogi S, Gupta RC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007;49(21):2120-8. doi:10.1016/j.jacc.2006.10.082.
25. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
Supplementary files
Review
For citations:
Uskach T.M., Safiullina A.A., Sharapova Yu.Sh., Amanatova V.A., Petrukhina A.A., Makeev M.I., Tereshchenko S.N. Four-year follow-up of a patient with mixed cardiomyopathy and an implanted cardiac contractility modulation device: a case report. Cardiovascular Therapy and Prevention. 2021;20(5):2811. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2811
Views:
1266
Email this article 
